<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01047995</url>
  </required_header>
  <id_info>
    <org_study_id>SSAT 031</org_study_id>
    <secondary_id>2008-008321-30</secondary_id>
    <nct_id>NCT01047995</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics (PK) Study of Once Daily Darunavir/Ritonavir and Twice and Once Daily Raltegravir in HIV-infected Subjects</brief_title>
  <official_title>Plasma and Intracellular Pharmacokinetics of Once Daily Darunavir/Ritonavir and Twice and Once Daily Raltegravir in HIV-infected Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St Stephens Aids Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St Stephens Aids Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to help us understand if the HIV drugs darunavir (taken with ritonavir) and
      raltegravir will affect each other when they are given at the same time.

      The purpose of the study is to assess the pharmacokinetics (how a drug is absorbed,
      distributed and eliminated from your body) of darunavir and ritonavir when these are taken
      with and without raltegravir.

      The duration of the study will be up to 50 days plus a screening visit which will take place
      up to 4 weeks prior to the start of the study, and a follow up visit which takes place 1-2
      weeks after the last dose of study medication.

      Subjects will continue to take 2 of their usual drugs (those called nucleoside reverse
      transcriptase inhibitors -NRTI) throughout the study.

      For the first 21 days subjects will take their usual NRTI plus raltegravir 400mg twice daily.
      After this, subjects will also receive either:

      Group 1) Darunavir/ritonavir 800mg/100mg once daily AND raltegravir 400mg twice daily or
      Group 2) Darunavir/ritonavir 800mg/100mg once daily AND raltegravir 800mg once daily

      Subjects will take this regimen for 14 days. Subjects will be randomly allocated to either
      Group 1 or 2. You will have an equal (50/50) chance of being allocated to Group 1 or 2.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The integrase inhibitor raltegravir has shown to a potent new agent for the treatment of HIV
      infection.

      When raltegravir and darunavir/ritonavir have been combined in the Benchmark studies, they
      provided an excellent virological response in highly experienced patients.

      Darunavir once daily use is increasing due to patients' preference for once daily regimens.

      Raltegravir has not shown any pharmacokinetic/pharmacodynamic relationship and doses of 100
      to 400 mg twice daily have shown similar virological responses. This may be due to
      intracellular drug accumulation.

      However, data on the use of darunavir/r plus raltegravir once daily and on raltegravir
      intracellular concentrations are not available.

      Whether raltegravir is efficacious when administered once daily is unknown. However,
      concentrations higher the IC95 of 33nM have been associated to a favourable virological
      response.

      Therefore, we would like to investigate the plasma and intracellular pharmacokinetics of
      darunavir/ritonavir and raltegravir when co-administered once daily in order to provide
      further data to support the use of these agents once daily, patients' preferred dosing
      schedule.

      Pharmacogenetics holds promise in HIV treatment because of the complexity and potential
      toxicity of multi antiretroviral drug therapies that are prescribed for long periods. Thus
      far, few candidate genes have been examined for a limited number of allelic variants, but a
      number of confirmed associations have already emerged.

      From a public health perspective, as antiretroviral medications become increasingly available
      to racially and ethnically diverse populations worldwide, understanding the genetic
      structures of each population may allow us to anticipate the impact of adverse responses,
      even in groups that were not represented in drug registration trials.

      The existing literature on pharmacogenetic determinants of antiretroviral drug exposure, drug
      toxicity, as well as genetic markers associated with the rate of disease progression
      underline the recent advances which occurred in the past few years.

      However, it is expected that larger-scale comprehensive genome approaches will profoundly
      change the landscape of knowledge in the future. Additional studies are needed to assess the
      implications for long-term responses to antiretroviral agents.

      For this reason we plan to collect a single blood sample from each participant in our
      intensive pharmacokinetic studies, such as this one, in order to be able to investigate the
      association between genetic polymorphisms in drug disposition genes (such as those encoding
      for cytochrome P450 isoenzymes or transmembrane transporters) and drug exposure. A candidate
      gene approach will be utilised to examine loci of interest. This procedure will provide
      potentially important information on genetic influences on plasma drug concentrations and
      give insight into how to improve the management of HIV-infected patients by individualising
      therapy. These studies will not be powered for genetic associations but will enable us to
      build a data base of genotype-phenotype. Prospective genetic studies would need to be planned
      based on these preliminary data.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Steady state plasma and intracellular concentrations of darunavir/ritonavir once daily with and without raltegravir and raltegravir twice and once daily</measure>
    <time_frame>50 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of darunavir/ritonavir and raltegravir when co-administered to HIV-infected subjects</measure>
    <time_frame>50 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between genetic polymorphisms in drug disposition genes and drug exposure</measure>
    <time_frame>50 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Phase 1, all subjects (n = 24): Raltegravir 400 mg twice daily for 21 days
Phase 2 Group 1 (n = 12): Darunavir/ritonavir 800/100 mg once daily plus raltegravir 400 mg twice daily for 14 days
Phase 3, all subjects (n = 24): Darunavir/ritonavir 800/100 mg once daily for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Phase 1, all subjects (n = 24): Raltegravir 400 mg twice daily for 21 days
Phase 2,
Group 2 (n = 12): Darunavir/ritonavir 800/100 mg once daily plus raltegravir 800 mg once daily for 14 days
Phase 3, all subjects (n = 24): Darunavir/ritonavir 800/100 mg once daily for 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir plus Darunavir/ritonavir</intervention_name>
    <description>Phase 1, all subjects (n = 24): Raltegravir 400 mg twice daily for 21 days
Phase 2 Group 1 (n = 12): Darunavir/ritonavir 800/100 mg once daily plus raltegravir 400 mg twice daily for 14 days
Phase 3, all subjects (n = 24): Darunavir/ritonavir 800/100 mg once daily for 14 days.</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>darunavir = TMC114</other_name>
    <other_name>ritonavir = Norvir trade name</other_name>
    <other_name>raltegravir = MK-0518, brand name Isentress</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir plus Darunavir/ritonavir</intervention_name>
    <description>Phase 1, all subjects (n = 24): Raltegravir 400 mg twice daily for 21 days
Phase 2
Group 2 (n = 12): Darunavir/ritonavir 800/100 mg once daily plus raltegravir 800 mg once daily for 14 days
Phase 3, all subjects (n = 24): Darunavir/ritonavir 800/100 mg once daily for 14 days.</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>darunavir = TMC114</other_name>
    <other_name>ritonavir = Norvir trade name</other_name>
    <other_name>raltegravir = MK-0518, brand name Isentress</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects must meet all of the following inclusion criteria within 28 days prior to the
        baseline visit:

          1. The ability to understand and sign a written informed consent form, prior to
             participation in any screening procedure and must be willing to comply with all study
             requirements.

          2. Male or non-pregnant, non-lactating females.

          3. Between 18 to 65 years, inclusive.

          4. Documented HIV-1 infection and plasma HIV RNA at screening visit below 400 copies/mL.

             (Note retesting of screening viral load is allowed).

          5. Women of childbearing potential (WOCBP) must be using an adequate method of
             contraception to avoid pregnancy throughout the study.

          6. CD4 count &gt; 100 at screening (Note retesting of screening CD4 count is allowed).

          7. Receiving an antiretroviral regimen including two NRTIs and an NNRTI or a boosted
             protease inhibitor or an integrase inhibitor, without any history of virological
             failure (history of drug switches is allowed only if the reason was
             tolerability/toxicity/convenience of dosing).

          8. Agrees not to change regimen, outside the study recommendations, from baseline until
             end of the treatment period unless this is medically indicated as decided by the
             treating physician.

        Exclusion Criteria:

        Subjects who meet any of the following exclusion criteria are not to be enrolled in this
        study.

          1. Any serious or active medical or psychiatric illness which, in the opinion of the
             investigator, would interfere with subject treatment, assessment, or compliance with
             the protocol. This would include any active clinically significant renal, cardiac,
             hepatic, pulmonary, vascular, metabolic disorders or malignancy.

          2. Have a body mass index (BMI) &gt;35

          3. Presence of any current active AIDS defining illness (Category C conditions according
             to the CDC Classification System for HIV Infection 1993) with the following
             exceptions:

             â€¢ Stable cutaneous Kaposi's Sarcoma

          4. Clinically relevant alcohol or drug use (positive urine drug screen, with the
             exception of cannabinoids) or history of alcohol or drug use considered by the
             Investigator to be sufficient to hinder compliance with treatment, follow-up
             procedures or evaluation of adverse events. Smoking is permitted, but tobacco intake
             should remain consistent throughout the study.

          5. The use of disallowed concomitant therapy (See Concomitant Medication and treatment,
             section 5.2).

          6. Females of childbearing potential without the use of effective non-hormonal birth
             control methods or not willing to continue practicing these birth control methods for
             at least 14 days after the end of the treatment period.

          7. Previous allergy to any of the constituents of the pharmaceuticals administered in
             this trial.

          8. Subjects with clinical or laboratory evidence of significantly decreased hepatic or
             renal function (as determined by the principal investigator).

          9. Exposure to any investigational drug or placebo within 4 weeks of first dose of study
             drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marta Boffito, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Stephen's AIDS Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Stephen's Centre, Chelsea and Westminster Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SW10 9NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Stephens Centre, Chelsea &amp; Westminster Hospital</name>
      <address>
        <city>London</city>
        <zip>SW10 9NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2010</study_first_submitted>
  <study_first_submitted_qc>January 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2010</study_first_posted>
  <last_update_submitted>January 12, 2010</last_update_submitted>
  <last_update_submitted_qc>January 12, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr Marta Boffito</name_title>
    <organization>St Stephen's AIDS Trust</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Darunavir</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

